The tweet was deleted by the author.
But we saved everything 🙂.
NeoGenomics has joined forces with Epic Aura to integrate genomic testing into Epic’s workflows, aiming to streamline processes and minimize errors for healthcare providers. Shares are down 4.8% on the day at $16.22.
NeoGenomics announced it has partnered with Epic Aura to integrate genomic testing capabilities directly into Epic workflows. The company said the integration aims to eliminate unnecessary manual processes and reduce errors caused by transcription and data re-entry. The update was published through NeoGenomics' own account.
View post on X Loading...
Shares of NeoGenomics opened with a gap down from $17.04 to $16.63. Price is tracking below the MA-20 and MA-50 but remains above the MA-200, reflecting a split daily structure. The nearest resistance is the prior weekly low at $16.42. Overall, the recent move is running against the broader bullish chart structure.
Traders should watch for a close above $16.42 to confirm buyers are willing to follow through. The session began with a gap lower from $17.04 to $16.63. Even so, over the coming trading week the upside probability stands at 63%, with downside at 37%, and the expected range is $15.79 to $16.64. A drop below $12.63 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.
Previously it was reported that NeoGenomics expanded its partnership with Indica Labs to advance its digital pathology capabilities. The new collaboration with Epic Aura represents a further evolution of NeoGenomics' technology ecosystem, and traders should monitor whether sustained price action above $16.42 can reestablish the stock’s bullish momentum.